Gynecologic cancer confers a large burden among women in the United States. Several evidence-based interventions are available to reduce the incidence, morbidity, and mortality from these cancers. The National Comprehensive Cancer Control Program (NCCCP) is uniquely positioned to implement these interventions in the US population. This review discusses progress and future directions for the NCCCP in preventing and controlling gynecologic cancer.
Get full access to this article
View all access options for this article.
References
1.
US Cancer Statistics Working Group. United States cancer statistics: 1999–2009 incidence and mortality web-based report. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2013. www.cdc.gov/uscs. 2013 April 24.
2.
MaxW, RiceDP, SungHYet al.The economic burden of gynecologic cancers in California. 1998. Gynecol Oncol, 2003Feb88:96–103.
3.
De VuystH, CliffordGM, NascimentoMCet al.Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis. Int J Cancer, 2009; 124:1626–1636.
4.
Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males: Advisory Committee on Immunization Practices (ACIP)2011. MMWR Morb Mortal Wkly Rep, 2011; 60:1705–1708.
5.
MarkowitzLE, DunneEF, SaraiyaMet al.Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)MMWR Recomm Rep, 2007; 56,RR-2:1–24.
6.
Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13–17 years: United States. 2011. MMWR Morb Mortal Wkly Rep, 2012; 61:671–677.
7.
Centers for Disease Control and Prevention (CDC). Cancer screening: United States. 2010. MMWR Morb Mortal Wkly Rep, 2012; 61:41–45.
ClaesE, Evers-KieboomsG, BoogaertsAet al.Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A, 2003; 116A:11–19.
10.
FinlayE, StopferJE, BurlingameEet al.Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet Test, 2008; 12:81–91.
11.
HadleyDW, JenkinsJ, DimondEet al.Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch Intern Med, 2003; 163:573–582.
12.
StewartSL, RimSH, RichardsTB. Gynecologic oncologists and ovarian cancer treatment: Avenues for improved survival. J Womens Health (Larchmt), 2011; 20:1257–1260. 10.1089/jwh.2011.3053.
13.
KhanK, CurtisCR, EkwuemeDUet al.Preventing cervical cancer: Overviews of the National Breast and Cervical Cancer Early Detection Program and two US immunization programs. Cancer, 2008; 113,10 Suppl:3004–3012.
14.
WingoPA, JamisonPM, HiattRAet al.Building the infrastructure for nationwide cancer surveillance and control: A comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) program (United States)Cancer Causes Control, 2003; 14:175–193.
15.
MajorA, StewartSL. Celebrating 10 years of the National Comprehensive Cancer Control Program, 1998 to 2008. Prev Chronic Dis, 2009; 6:A133.
16.
Belle IsleL, PlesciaM, La PortaMet al.In conclusion: Looking to the future of comprehensive cancer control. Cancer Causes Control, 2010; 21:2049–2057.
17.
Centers for Disease Control and Prevention. Stories of success: National Comprehensive Cancer Control Program: Comprehensive cancer control in action. Atlanta: Centers for Disease Control and Prevention, National Comprehensive Cancer Control Program, 2012. http://www.cdc.gov/cancer/ncccp/state.htm. 2013 April 24.
18.
StewartSL, RimSH, TriversKF. Summary and impact of ovarian cancer research and programmatic activities at the Centers for Disease Control and Prevention. J Womens Health (Larchmt), 2010; 19:1427–1432.
19.
Surveillance Research Program, National Cancer Institute. Fast stats: An interactive tool for access to SEER cancer statistics. http://seer.cancer.gov/faststats. 2013 April 24.
20.
LaufmanJD, DuquetteD, TrepanierA. Evaluation of state comprehensive cancer control plans for genomics content. Prev Chronic Dis, 2012; 9:E176.
21.
MadisonT, SchottenfeldD, JamesSAet al.Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. Am J Public Health, 2004; 94:2104–2111.
22.
RimSH, PolonecL, StewartSLet al.A national initiative for women and healthcare providers: CDC's Inside knowledge: Get the Facts About Gynecologic Cancer campaign. J Womens Health (Larchmt), 2011; 20:1579–1585.
23.
CarterJS, DownsLSJr.Vulvar and vaginal cancer. Obstet Gynecol Clin North Am, 2012; 39:213–231.
24.
HamplM, SarajuuriH, WentzensenNet al.Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol, 2006; 108:1361–1368.
25.
JemalA, SimardEP, DorellCet al.Annual Report to the Nation on the Status of Cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst, 2013; 105:175–201.
26.
CressRD, BauerK, O'MalleyCDet al.Surgical staging of early stage epithelial ovarian cancer: Results from the CDC-NPCR ovarian patterns of care study. Gynecol Oncol, 2011; 121:94–99.
27.
ChanJK, ShermanAE, KappDSet al.Influence of gynecologic oncologists on the survival of patients with endometrial cancer. J Clin Oncol, 2011; 29:832–838.
28.
GershensonDM. Why American women are not receiving state-of-the-art gynecologic cancer care. Cancer J, 2001; 7:450–457.
29.
Office of Disease Prevention and Health Promotion. Healthy People. 2020Washington, DC: US Department of Health and Human Serviceswww.healthypeople.gov/2020/topicsobjectives2020/default.aspx. 2013 April 24.
